KPRX Stock Overview
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Kiora Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.28 |
| 52 Week High | US$39.18 |
| 52 Week Low | US$2.32 |
| Beta | 0.27 |
| 1 Month Change | -11.35% |
| 3 Month Change | -44.31% |
| 1 Year Change | -88.01% |
| 3 Year Change | -98.81% |
| 5 Year Change | -99.20% |
| Change since IPO | -99.90% |
Recent News & Updates
Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Oct 13Kiora Pharma announces 1-for-40 reverse stock split
Sep 26Recent updates
Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Oct 13Kiora Pharma announces 1-for-40 reverse stock split
Sep 26Kiora Pharmaceuticals reports 1H results
Aug 12Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing
Jul 28Kiora Pharmaceuticals prices $5.2M underwritten public offering
Jul 22Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201
Jul 05EyeGate Pharmaceuticals announces $8M private placement
Jan 06EyeGate surge in premarket as it acquires Panoptes Pharma for $4M
Dec 21Shareholder Returns
| KPRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.1% | -0.7% | 0.9% |
| 1Y | -88.0% | 4.9% | -10.9% |
Return vs Industry: KPRX underperformed the US Pharmaceuticals industry which returned 4.6% over the past year.
Return vs Market: KPRX underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| KPRX volatility | |
|---|---|
| KPRX Average Weekly Movement | 19.0% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: KPRX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: KPRX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 14 | Brian Strem | https://www.kiorapharma.com |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery.
Kiora Pharmaceuticals, Inc. Fundamentals Summary
| KPRX fundamental statistics | |
|---|---|
| Market Cap | US$5.59m |
| Earnings (TTM) | -US$17.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs KPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KPRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$5.04m |
| Gross Profit | -US$5.04m |
| Other Expenses | US$12.23m |
| Earnings | -US$17.27m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.14 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KPRX perform over the long term?
See historical performance and comparison